Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Viridian Therapeutics Inc (NQ: VRDN )

11.81 -0.19 (-1.58%)
Streaming Delayed Price Updated: 10:26 AM EDT, Jun 4, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Viridian Therapeutics Inc

< Previous 1 2 3 4 5 Next >
Viridian Therapeutics Enters Autoinjector Pen Device Customization and Supply Agreement with Ypsomed AG for Subcutaneous Drug Delivery in Thyroid Eye Disease
From Viridian Therapeutics, Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Tuesday
  On Tuesday, 647 companies set new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
  During Thursday's session, 406 companies made new 52-week lows. 
Via Benzinga
Analyst Ratings for Viridian Therapeutics
Via Benzinga
9 Analysts Have This to Say About Viridian Therapeutics
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
  On Tuesday, 386 stocks made new 52-week lows. 
Via Benzinga
Why Are Viridian Therapeutics Shares Falling Today
Viridian Therapeutics Inc (NASDAQ: VRDN) released preliminary data from its ongoing Phase 1/2 trial of VRDN-001 for 
Via Benzinga
Viridian Appoints Sarah Gheuens, M.D., Ph.D., to its Board of Directors
From Viridian Therapeutics, Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Thursday
  During the session on Thursday, 461 stocks hit new 52-week lows. 
Via Benzinga
11 Analysts Have This to Say About Viridian Therapeutics
Via Benzinga
Viridian Therapeutics Announces Presentations at Multiple Medical Meetings in September
From Viridian Therapeutics, Inc.
Via Business Wire
Global Payments To Rally Around 17%? Here Are 10 Other Analyst Forecasts For Thursday
Keybanc cut the price target for i3 Verticals, Inc. (NASDAQ: IIIV) from $28 to $26. Keybanc analyst Josh Beck maintained an Overweight rating. i3 Verticals shares fell 2.9% to close at $22.76 on... 
Via Benzinga
Viridian Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
From Viridian Therapeutics, Inc.
Via Business Wire
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Viridian Therapeutics, Inc.
Via Business Wire
2 Growth Stocks Wall Street Analysts Think Can Double in Value
Is now a good time to buy these promising healthcare stocks? 
Via The Motley Fool
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Why Siyata Mobile Shares Are Trading Lower By 21%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers CytoMed Therapeutics Limited (NASDAQ: GDTC) shares climbed 129.5% to $8.01 after gaining 9% on Monday. 
Via Benzinga
Why Shares of Viridian Therapeutics Are Falling Tuesday
The company announced preliminary trial results for its lead therapy. 
Via The Motley Fool
Viridian Wants To Take On Horizon; Why This Update In Thyroid Eye Disease Fell Flat
Shares tumbled after the biotech company unveiled the results of its chronic TED treatment. 
Via Investor's Business Daily
Why These 2 Nasdaq Biotech Stocks Fell Hard Tuesday Morning
Broader markets seemed likely to start out on a positive note despite these two outliers. 
Via The Motley Fool
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Why Better Therapeutics Are Trading Higher By 51%; Here Are 20 Stocks Moving Premarket
Gainers CytoMed Therapeutics Limited (NASDAQ: GDTC) shares surged 109.2% to $7.30 in pre-market trading after gaining 9% on Monday. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
It's time for another breakdown of the biggest pre-market stock movers as we check out all of the shares rising and falling on Tuesday! 
Via InvestorPlace
JetBlue Airways, VOXX International And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures traded slightly higher this morning. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)
From Viridian Therapeutics, Inc.
Via Business Wire
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Viridian Therapeutics, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For June 14, 2023
Via Benzinga
Viridian Therapeutics Announces Presentations at the 2023 Annual Meeting of the Endocrine Society
From Viridian Therapeutics, Inc.
Via Business Wire
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Viridian Therapeutics, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For May 30, 2023
Via Benzinga
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.